Haloperidol (Haloperidol) Patent Expiration, LOE Window & CMS Spending

Haloperidol (Haloperidol) by Sagent Pharms: Off-Patent Genericized (AB Competition), 14 AB generics, $41.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSagent Pharms
FDA Application & PathwayN020074 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors14
2024 CMS Total Public Spend$41.9M
2024 Medicare Part D Spend$27.4M
2024 Medicaid Spend$14.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel